Adoptive cell transfer as personalized immunotherapy for human cancer
Science2015Vol. 348(6230), pp. 62–68
Citations Over TimeTop 1% of 2015 papers
Abstract
Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves administration to the cancer-bearing host of immune cells with direct anticancer activity. ACT using naturally occurring tumor-reactive lymphocytes has mediated durable, complete regressions in patients with melanoma, probably by targeting somatic mutations exclusive to each cancer. These results have expanded the reach of ACT to the treatment of common epithelial cancers. In addition, the ability to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors has further extended the successful application of ACT for cancer treatment.
Related Papers
- → Preclinical and clinical studies of CAR-NK-cell therapies for malignancies(2022)82 cited
- → Strategies to overcome the side effects of chimeric antigen receptor T cell therapy(2022)7 cited
- → Chimeric Antigen Receptor T-cell Therapy Beyond Cancer: Current Practice and Future Prospects(2020)5 cited
- → Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory(2018)5 cited
- → OPPORTUNITIES AND CHALLENGES FOR CAR T-CELL THERAPY IN CANCER(2022)